AstraZeneca's Truqap Plus Faslodex Recommended For EU Approval By CHMP For Advanced Breast Cancer

(RTTNews) - AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast ca https://www.nasdaq.com/articles/astrazenecas-truqap-plus-faslodex-recommended-for-eu-approval-by-chmp-for-advanced-breast